LENZ Therapeutics (LENZ) Scheduled to Post Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, analysts expect LENZ Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Performance

NASDAQ LENZ opened at $27.93 on Monday. The stock’s 50 day moving average is $24.03 and its 200 day moving average is $20.74. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $31.00.

Analyst Upgrades and Downgrades

LENZ has been the subject of several research reports. Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 price target for the company. Piper Sandler reissued an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. HC Wainwright initiated coverage on LENZ Therapeutics in a research note on Monday, August 12th. They set a “buy” rating and a $38.00 price objective for the company. Finally, William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.